Loading
A phase 3 trial of Retlirafusp alfa run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active.
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer is a phase 3 interventional study registered as NCT04950322 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 737 participants enrolled, started 2021-12-06. Conditions listed: Gastric or Gastroesophageal Junction Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Retlirafusp alfa, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer.
Shares Retlirafusp alfa, Jiangsu Hengrui Pharmaceuticals, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Bispecific antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors.
Shares Retlirafusp alfa, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/